Year
2025202420232022202120202019201720162015201420132012201120102009200820072006200520042003200220012000
Edition number
№13 (366)№14 (367)№11 (364)№12 (365)№s5№10 (363)№s4№9 (362)№8 (361)№s3№6 (359)№5 (358)№s2№s1№4 (357)№КР3№3 (356)№2 (355)№1 (354)
№7 (360) / 2018
A.V. Novik
PRINCIPLES OF MODERN IMMUNOTHERAPY10-18
T.Yu. Semiglazova (1, 2), I.V. Berlev (1, 2), E.A. Ulrikh (1, 3), V.V. Semiglazov (1, 3), A.E. Protasova (2, 4), N.A. Brish (1), E.A. Korobeynikova (1), Yu.V. Alekseeva (1), L.V. Filatova (1, 2), A.I. Semenova (1), D.Kh. Latipova (1), G.M. Teletaeva (1), E.V. Tkachenko (1), V.V. Klimenko (1), G.A. Dashyan (1), S.A. Protsenko (1), R.M. Paltuev (1), A.F. Urmancheeva (1, 2), P.V. Krivorotko (1, 2), V.F. Semiglazov (1, 2)
GONADOTROPIN-RELEASING HORMONE AGONISTS-INDUCED OVARIAN SUPPRESSION IN EARLY BREAST CANCER19-25
L.V. Filatova (1, 2), M.S. Motalkina (1), E.V. Kharchenko (1), I.V. Ishmatova (1), I.S. Zyuzgin (1), P.S. Shilo (1), Yu.A. Oleinik (1), Yu.A. Chudinovskikh (1), T.Yu. Semiglazova (1, 2)
TREATMENT OF RELAPSES AND RESISTANT FORMS OF HODGKIN’S LYMPHOMA26-32
A.D. Darenskaya, N.V. Dobrova, E.V. Stepanova
INTERCELLULAR ADHESION MOLECULES (E-CADHERIN, β-CATENIN) IN COLORECTAL CANCER: CHARACTERISTICS; ROLE IN MECHANISMS OF TUMOR INVASION, METASTASIS AND REGULATION OF TUMOR PROGRESSION; INFLUENCE ON PROGNOSIS (LITERATURE REVIEW)33-39
N.V. Zhukova (1), R.V. Orlova (1, 2), N.Yu. Antimonik (1), S.I. Kutukova (1, 3), N.P. Belyak (1), N.V. Popova (1)
EXPERIENCE OF TREATMENT with ANTI-PD-1: FROM WORLD STANDARDS TO REAL CLINICAL PRACTICE (CLINICAL OBSERVATION)40-44
D.D. Sakaeva, A.I. Iskhakova, R.I. Kunafina
CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE45-49
S.I. Kutukova (1, 2)
MODERN APPROACHES TO THE CHOICE OF THERAPY OF LOCALLY ADVANCED AND RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA: WHAT IS THE BASIS FOR THE CHOICE OF THERAPY IN CLINICAL PRACTICE?50-56
T.V. Gorodnova (1), A.P. Sokolenko (1), A.O. Ivantsov (1), Kh.B. Kotiv (1), M.G. Yakovleva (1), O.N. Mikheeva (2), G.I. Mikhaylyuk (2), A.S. Lisyanskaya (3, 4), K.D. Guseinov (1), E.A. Nekrasova (1), O.A. Smirnova (1), A.A. Sidoruk (1), N.E. Bondarev (1), N.S. Matveeva (1), I.E. Meshkova (1), N.A. Mikaya (1), S.V. Petrik (1), G.M. Manikhas (3, 4), S.A. Protsenko (1), I.V. Berlev (1), A.M. Belyaev (1), E.N. Imyanitov (1)
SYSTEMIC THERAPY FOR ADVANCED OVARIAN CANCER IN BRCA1 MUTATION CARRIERS – NEW THERAPEUTIC APPROACHES: RESULTS OF A PROSPECTIVE NON-RANDOMIZED MULTI-CENTER STUDY57-63
E.M. Slonimskaya (1, 2), P.V. Kazantseva (1), N.V. Litviakov (1, 3), M.M. Tsyganov (1), M.K. Ibragimova (1, 3), A.V. Doroshenko (1), R.U. Vernadsky (1), M.A. Vostrikova (2), N.A. Lushnikova (2)
EXPERIENCE OF PERSONALIZED APPOINTMENT OF NEOADJUVANT CHEMOTHERAPY FOR PATIENT WITH BREAST CANCER: A PROSPECTIVE STUDY64-70
P.I. Shabalkin
ANALYSIS OF INFLUENCE ON THE BUDGET OF THE RUSSIAN FEDERATION OF THE USE OF ORAL VINORELBINE FOR THE TREATMENT OF METASTATIC BREAST CANCER71-75
L.Yu. Vladimirova, N.A. Abramova, A.A. Lyanova, A.E. Storozhakova, I.L. Popova, N.M. Tikhanovskaya, K.A. Novoselova, L.A. Ryadinskaya, M.O. Ezhova, E.A. Dzhenkova
DENOSUMAB IN TREATMENT OF BONE METASTASES FROM SOLID TUMORS76-81
V.M. Moiseenko (1), F.V. Moiseenko (1, 2, 3), N.M. Volkov (1), G.A. Yanus (2), E.Sh. Kuligina (2), A.P. Sokolenko (2), S.N. Aleksakhina (2), V.A. Chubenko (1), K.S. Kozyreva (2), N.Kh. Abduloeva (1), M.M. Kramchaninov (1), A.S. Zhuravlev (1), V.A. Khinshtein (1), K.V. Shelekhova (1), A.A. Kudryavtsev (1), A.V. Myslik (1), A.O. Ivantsov (2), A.R. Venina (2), E.V. Preobrazhenskaya (2, 4), N.V. Mityushkina (2), A.G. Ievleva (2, 4), E.N. Imyanitov (2, 4)
Prospective II phase study on the evaluation of the efficacy of monotherapy with cetuximab as the first-line treatment for patients with metastatic colorectal cancer with wild-type KRas, NRas, and BRAF genes82-88
A.D. Darenskaya, N.V. Dobrova, D.A. Khochenkov, E.V. Stepanova
PROGNOSTIC SIGNIFICANCE OF THE E-CADHERIN EXPRESSION LEVEL IN PRIMARY TUMORS OF THE COLON IN PATIENTS WITH METASTATIC COLORECTAL CANCER, RECEIVED NEW CHEMOTHERAPY REGIMEN BASED ON TRIPLE COMBINATION: IRINOTECAN+OXALIPLATIN+CONTINUOUS-INFUSION 5-FLUOROURACIL AS A FIRST-LINE TREATMENT89-96
V.S. Fomin
POSTOPERATIVE ADYNAMIC ILEUS: PREVENTION AND TREATMENT97-101
T.A. Titova, N.S. Besova, V.A. Gorbunova, A.A. Fedenko, O.A. Malikhova
RAMUCIRUMAB IN A COMBINATION WITH IRINOTECAN-BASED TWO-COMPONENT THERAPY REGIMEN AS THE SECOND LINE FOR THE TREATMENT OF DISSEMINATED GASTRIC CANCER. CASE REPORT102-104
G.A. Khakimov (1), Kh.I. Dzhumaniezov (1), Sh.Sh. Kadyrov (1), Sh.V. Ziyaev (1), G.G. Khakimova (2)
SUCCESSFUL TREATMENT OF THE COMPLICATED FORM OF NON-HODGKIN’S LYMPHOMA OF THE CECUM. CASE REPORT105-111
